NCT07296809 SKB500 Combinations in Patients With Small Cell Lung Cancer
| NCT ID | NCT07296809 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Condition | Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-01-30 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2026-01-30 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants between 18 and 75 years old. 2. Histologically or cytologically confirmed Extensive-stage small cell lung cancer (ES-SCLC): * Cohort 1: participant has received or not received prior systemic treatment, with no more than 1 prior systemic therapy in the extensive stage. * Cohort 2\~3: participant has received no prior systemic treatment. 3. Agree to provide fresh or archival tumor tissue for biomarker analysis. 4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy \>= 12 weeks. 7. Has adequate organ and bone marrow functions. 8. Has recovered to grade ≤ 1 of prior anti-cancer treatment toxicities. 9. Effective contraceptive methods should be used during the study and for 6 months after the end of treatment. 10. Voluntarily join this study, sign the informed consent form, and can comply with the protocol-specified visits and procedures. Exclusion Criteria: 1. The pathology suggests the presence of both non-small cell carcinoma and small cell carcinoma components. 2. Has previously received medications with the same target or the same toxins. 3. Presence of spinal cord compression or clinically active central nervous system metastases. 4. Presence of clinical symptoms caused by tumor invasion or compression of important organs and blood vessels. 5. Severe infection within 4 weeks or active infection requiring systemic anti-infective treatment within 2 weeks prior to the first dose. 6. With peripheral neuropathy of grade ≥ 2. 7. History of any serious, life threatening, or permanently discontinuing adverse events mediated by immunotherapy, including infusion reactions. 8. Presence of uncontrolled concurrent diseases, including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, Severe active peptic ulcer, gastrointestinal bleeding, gastrointestinal perforation, intestinal obstruction, etc. 9. Serious or uncontrolled heart disease or clinical symptoms requiring treatment. 10. History of interstitial lung disease (ILD) /noninfectious pneumonitis that require steroid treatment, or currently has ILD/noninfectious pneumonitis. 11. Clinical severe lung damage caused by concurrent lung disease. 12. Uncontrolled hypertension, diabetes, or repeated drainage of pleural effusion/pericardial effusion/ abdominal effusion. 13. Pregnant or lactating women. 14. Rapid disease deterioration in the screening process.
Contact & Investigator
Yilong Wu
PRINCIPAL INVESTIGATOR
Guangdong Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT07296809 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07296809 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07296809 currently recruiting?
Yes, NCT07296809 is actively recruiting participants. Contact the research team at qingyan@kelun.com for enrollment information.
Where is the NCT07296809 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07296809 clinical trial?
NCT07296809 is sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. The principal investigator is Yilong Wu at Guangdong Provincial People's Hospital. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.